Immune checkpoint inhibitor-related gastrointestinal adverse events: a disproportionality analysis based on the FAERS database
Our pharmacovigilance analysis reveals a high risk of gastrointestinal adverse events with ICI therapy, especially anti-CTLA-4. Stage IV disease, concurrent targeted therapies, and anti-CTLA-4 therapy or combination therapy further increase this risk, highlighting the need for personalized treatment strategies.
Authors
- Yongjiu Chen
- Aiwen Wu (ORCID: https://orcid.org/0000-0003-1877-7005)
- Dengbo Ji (ORCID: https://orcid.org/0000-0002-5164-7344)
- Yuye Gao
- Jun‐Peng Pei (ORCID: https://orcid.org/0000-0002-1876-3204)
- Yong‐Lin Huang
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1080/14740338.2025.2574669
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00